Pulse Biosciences (PLSE) Equity Average (2016 - 2025)

Pulse Biosciences' Equity Average history runs 10 years deep, the most recent figure standing at $86.7 million for Q4 2025.

• In Q4 2025, Equity Average fell 10.64% year-over-year to $86.7 million; the TTM figure through Dec 2025 stood at $86.7 million (down 10.64% YoY), while the FY2025 annual figure was $97.8 million, up 22.8% from the prior year.
• Equity Average was $86.7 million for Q4 2025 at Pulse Biosciences, down from $98.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $116.7 million in Q1 2025 to a low of -$6.5 million in Q1 2023.
• Historically, Equity Average has averaged $49.6 million across 5 years, with a median of $43.1 million in 2021.
• Biggest YoY gain for Equity Average was 2348.74% in 2023; the steepest drop was 119.82% in 2023.
• A 5-year view of Equity Average shows it stood at $45.9 million in 2021, then tumbled by 95.7% to $2.0 million in 2022, then surged by 2348.74% to $48.3 million in 2023, then jumped by 101.02% to $97.0 million in 2024, then slipped by 10.64% to $86.7 million in 2025.
• The last three Equity Average figures came in at $86.7 million (Q4 2025), $98.6 million (Q3 2025), and $111.5 million (Q2 2025), per Business Quant data.